

**Priority Colorectal Trials  
Participating Sites in Georgia**

Identified by the Scientific Leadership Council on GI Coalition of Cancer Cooperative Groups

	<b>C80405</b>	<b>ECOG- E4203</b>	<b>ECOG- E5202</b>	<b>ECOG- E5204</b>	<b>NCCTG- N0147</b>	<b>NSABP-C- 08*</b>	<b>NSABP- C-09</b>	<b>NSABP- R-04</b>
Atlanta Cancer Care 678-287-1241	X		X	X	X	X		X
Atlanta VA Med Ctr 404-321-6111ext. 2457		X			X			
Augusta Onc Assc 706-821-2944			X		X			
Augusta VA Med Ctr 706-721-0193						X		
DeKalb Med Ctr 404-508-4320	X		X	X	X	X		X
Emory University 404-778-4469		X	X			X		
Georgia Cancer Specialists 770-496-9400	X		X	X	X	X		X
Gwinnett Hospital System 678-442-2666	X		X	X	X	X		X
John B. Amos Cancer Center 706-660-6404	X		X	X	X			X
Medical College of Georgia 706-721-6136						X		X
Medical Ctr of Central Georgia 478-633-1738	X			X		X		
Memorial Med Ctr 912-350-7887	X		X		X	X	X	X
NE Georgia Cancer Care 706-353-5006					X	X		X
NE Georgia Med Ctr 770-533-8820	X		X		X	X		
Northside Hospital 404-303-3355	X		X	X	X	X		X
Northwest Georgia Oncology Centers 770-	X		X	X	X	X		X
Phoebe Putney 229-312-0405	X					X		X
Piedmont Hospital 404-605-2887	X		X	X	X	X		X
Pearlman Cancer Ctr 229-259-4600	X		X		X			
Southern Reg Med Ctr 770-991-8611	X		X	X	X	X		X
St. Joseph Health System 404-851-7119	X		X	X	X	X		X
St. Joseph/Candler 912-819-6194	X			X	X	X		X
Wellstar Cobb 770-732-4648	X		X	X	X	X		X
Wellstar Kennestone 678-594-4300	X		X	X	X	X		X

\*Shaded area indicates trial closing

**Priority Colorectal Trial Descriptions:**

**CALGB-C80405:** A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

**ECOG-E4203:** Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer

**ECOG-E5202:** Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer

**ECOG-E5204:** Phase III Randomized Study of Adjuvant Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients Who Have Undergone Surgery and Neoadjuvant Chemoradiotherapy for Stage II or III Rectal Cancer

**NCCTG-N0147:** A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer

**NSABP-C-08:** A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon

**NSABP-C-09:** Phase III Randomized Study of Adjuvant Therapy Comprising Oxaliplatin and Capecitabine With Versus Without Hepatic Arterial Infusion of Floxuridine in Patients Undergoing Surgical Resection and/or Ablation for Hepatic Metastases From Colorectal Cancer

**NSABP-R-04:** Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer

\* Information is accurate as of November 2006.